You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

ORAVERSE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Oraverse

A generic version of ORAVERSE was approved as phentolamine mesylate by HIKMA on March 11th, 1998.

  Try a Trial

Drug patent expirations by year for ORAVERSE
Drug Prices for ORAVERSE

See drug prices for ORAVERSE

Recent Clinical Trials for ORAVERSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cairo UniversityPhase 3
sara nabilPhase 3
Dalhousie UniversityPhase 4

See all ORAVERSE clinical trials

Pharmacology for ORAVERSE

US Patents and Regulatory Information for ORAVERSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ORAVERSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 ⤷  Try a Trial ⤷  Try a Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 ⤷  Try a Trial ⤷  Try a Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 ⤷  Try a Trial ⤷  Try a Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 ⤷  Try a Trial ⤷  Try a Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ORAVERSE

See the table below for patents covering ORAVERSE around the world.

Country Patent Number Title Estimated Expiration
Portugal 1280531 ⤷  Try a Trial
Spain 2281418 ⤷  Try a Trial
Canada 2489526 FORMULATIONS STABILISEES D'ANTAGONISTES DE RECEPTEURS ADRENERGIQUES ALPHA ET LEUR UTILISATION (STABILIZED FORMULATIONS OF ALPHA ADRENERGIC RECEPTOR ANTAGONISTS AND USES THEREOF) ⤷  Try a Trial
Australia 5984801 ⤷  Try a Trial
Japan 2005533869 ⤷  Try a Trial
Canada 2408417 METHODES ET KITS D'ANESTHESIE LOCALE (LOCAL ANESTHETIC METHODS AND KITS) ⤷  Try a Trial
Brazil 0311965 Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.